Sanofi India Limited (SANOFI) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹3,337.3 (+1.07% day change)
Key ratios
- P/E ratio
- 23.53
- P/B ratio
- 12.56
- ROE (%)
- 43.61
- ROCE (%)
- 59.47
- Debt/Equity
- 0.02
- Dividend yield (%)
- 4.7
- Market cap (₹ Cr)
- 7,686.01
Forensic checks
Piotroski F-Score: 8/9 · Altman Z-Score: 9.72 · Beneish M-Score: -3.22
InvestSights quality score
67.1/100 — Above Average (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q1 FY27)
AI summary: The single most important signal from this concall is the structural divergence between Sanofi India's two business engines. The diabetes franchise — anchored by Toujeo, Lantus, and Soliqua — is delivering genuine momentum, with 14% Q2 growth, 17% H1 growth, a 70% surge in public sector volumes, and PBT expanding from ₹94 crores to ₹112 crores in Q2, alongside a 27%…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.